{"id":88949,"date":"2026-10-29T01:15:00","date_gmt":"2026-10-29T01:15:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=88949"},"modified":"2026-10-29T01:58:23","modified_gmt":"2026-10-29T01:58:23","slug":"junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma"},"content":{"rendered":"<p>SHANGHAI, China, Oct.  28, 2026  (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for the company\u2019s product, toripalimab injection (subcutaneous injection) (code: JS001sc) in combination with disitamab vedotin for the treatment of HER2-expressing (HER2 expression is defined as HER2 immunohistochemistry results of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma (UC) has recently been accepted by the China National Medical Products Administration (NMPA). To date, the new drug application for JS001sc, in respect of all 13 approved indications of toripalimab (intravenous injection) (code: JS001), have been accepted.<\/p>\n<p>JS001sc is a subcutaneous injection formulation developed by Junshi Biosciences based on the marketed product, toripalimab injection. It is the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to enter the new drug application stage, and is expected to bring convenient administration to patients.<\/p>\n<p>Immuno-oncology (I-O) therapies, represented by anti-PD-1 monoclonal antibodies, have become cornerstone therapies for the treatment of various malignant tumors. However, immuno-oncology drugs currently available in China are predominantly formulated for intravenous infusion, which not only requires prolonged infusion times but also causes significant inconvenience to patients during treatment. Consequently, there is an urgent clinical need to improve the convenience of immunotherapy.<\/p>\n<p>In November 2025, a multi-center, open-label, randomized controlled Phase 3 clinical study to compare JS001sc and toripalimab injection in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer met the primary endpoint.<\/p>\n<p>In March 2026, the Phase 3 clinical study of JS001sc in combination with chemotherapy as a first-line treatment for non-squamous non-small-cell lung cancer was successfully selected for an oral presentation at the European Lung Cancer Congress 2026 (ELCC 2026). The study results demonstrated that the drug exposure of toripalimab subcutaneous injection was non-inferior to that of the intravenous formulation of toripalimab, with comparable clinical efficacy and safety profiles, and is expected to provide patients with a new, more convenient immunotherapy option.<\/p>\n<p>In March 2026, the new drug application of JS001sc for 12 indications for the treatment of tumors was accepted by the NMPA, making it the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to enter the new drug application stage.<\/p>\n<p><strong>About Junshi Biosciences<\/strong><\/p>\n<p>Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for innovative drug discovery, strong biotechnology R&amp;D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small-molecule drugs, ADCs, bsAb\/msAb, fusion proteins, nucleic acid drugs and vaccines. Five of the company\u2019s products have received marketing authorizations in China and international markets, one of which is toripalimab, China\u2019s domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 50 countries and regions including China, the US, and Europe.<\/p>\n<p>With a mission of \u201cproviding patients with world-class, trustworthy, affordable, and innovative drugs,\u201d Junshi Biosciences is \u201cIn China, For Global.\u201d The company currently employs more than 3,000 people worldwide. Headquartered in Shanghai, China, it has a business presence in multiple countries and regions around the world. For more information, please visit: http:\/\/www.junshipharma.com.<\/p>\n<p><strong>Junshi Biosciences Contact Information<\/strong><\/p>\n<p>IR Team:<\/p>\n<p>Junshi Biosciences<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DdSDhUSyvKRP8zGus63UzUFsxrhpT3b9A8A6M4yhDe3xCK1HYhS3yBSKxaOzL2Y-tV4QyT9G6q32WEs8peKhiDeSXcAFqpzUi1l-qqSPWKg=\" rel=\"nofollow\" target=\"_blank\" title=\"info@junshipharma.com\">info@junshipharma.com<\/a><\/p>\n<p>+ 86 021-6105 8800<\/p>\n<p>PR Team:<\/p>\n<p>Junshi Biosciences<\/p>\n<p>Zhi Li<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WjrF3Pl3xPEncLYwNzKcV__uQL_RipemxoraseHrcWVtcukd3SgS3Q_s6tM-wvndAq6VTxIaY2QX-sWDJBC9u-neZvSjJ8EruczgbxV0w0cz82ZVuv1W5oCnH5mkXRWF\" rel=\"nofollow\" target=\"_blank\" title=\"zhi_li@junshipharma.com\">zhi_li@junshipharma.com<\/a><\/p>\n<p>+ 86 021-6105 8800<\/p>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MmU1ODljYjctNWFjMy00ZGUwLWExYzgtY2I0ODkxNzQ3OTU4LTEyMDY5MjgtMjAyNi0xMC0yOS1lbg==\/tiny\/Junshi-Biosciences.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for the company\u2019s product, toripalimab injection (subcutaneous injection) (code: JS001sc) in combination with disitamab [&#8230;]\n","protected":false},"author":1,"featured_media":88950,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-88949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T01:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-29T01:58:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/10\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma\",\"datePublished\":\"2026-10-29T01:15:00+00:00\",\"dateModified\":\"2026-10-29T01:58:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"},\"wordCount\":609,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-10-29T01:15:00+00:00\",\"dateModified\":\"2026-10-29T01:58:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma","og_description":"SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading","og_url":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-10-29T01:15:00+00:00","article_modified_time":"2026-10-29T01:58:23+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/10\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma.gif","type":"image\/gif"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma","datePublished":"2026-10-29T01:15:00+00:00","dateModified":"2026-10-29T01:58:23+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"wordCount":609,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","url":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-10-29T01:15:00+00:00","dateModified":"2026-10-29T01:58:23+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=88949"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88949\/revisions"}],"predecessor-version":[{"id":88951,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88949\/revisions\/88951"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/88950"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=88949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=88949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=88949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}